AstraZeneca's Fasenra Falls Short In Smoker's Lung Trial
1. AZN released Phase 3 trial results for Fasenra showing numerical improvement. 2. Fasenra did not achieve statistical significance in treating COPD. 3. Saphnelo's trial results indicated significant reduction in lupus disease activity. 4. Fasenra is approved in over 80 countries, Saphnelo in over 70. 5. AZN stock increased by 0.11% to $77.64 following the announcements.